UY28235A1 - Formulación dispersable de un agente antiinflamatorio - Google Patents

Formulación dispersable de un agente antiinflamatorio

Info

Publication number
UY28235A1
UY28235A1 UY28235A UY28235A UY28235A1 UY 28235 A1 UY28235 A1 UY 28235A1 UY 28235 A UY28235 A UY 28235A UY 28235 A UY28235 A UY 28235A UY 28235 A1 UY28235 A1 UY 28235A1
Authority
UY
Uruguay
Prior art keywords
inflammatory agent
organ
composition
fluid
dispersible
Prior art date
Application number
UY28235A
Other languages
English (en)
Inventor
Nancy J Britten
John W Burns
Jeffrey L Watts
John W Hallberg
Niki A Waldron
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of UY28235A1 publication Critical patent/UY28235A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Procedimiento para tratamiento de una afección antiinflamatoria en un órgano que contiene fluido que tiene un orificio natural exterior, tal como la ubre de un animal productor de leche o un oído. El procedimiento comprende la administración, al órgano a través del orificio exterior, de una composición farmacéutica que comprende un agente antiinflamatorio y un vehículo que comprende un aceite anfipático que es dispersable en agua e insoluble en etanol, cera microcristalina y un vehículo no acuoso farmacéuticamente aceptable. Composición que comprende el agente antiinflamatorio. La composición es fácilmente dispersable en el fluido del órgano que contiene fluido.
UY28235A 2003-03-20 2004-03-18 Formulación dispersable de un agente antiinflamatorio UY28235A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45632503P 2003-03-20 2003-03-20

Publications (1)

Publication Number Publication Date
UY28235A1 true UY28235A1 (es) 2004-11-08

Family

ID=33030094

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28235A UY28235A1 (es) 2003-03-20 2004-03-18 Formulación dispersable de un agente antiinflamatorio

Country Status (26)

Country Link
US (1) US20040235803A1 (es)
EP (1) EP1608407B1 (es)
JP (1) JP2006520779A (es)
KR (1) KR100717433B1 (es)
CN (1) CN1761487A (es)
AR (1) AR043650A1 (es)
AT (1) ATE337793T1 (es)
AU (1) AU2004222523A1 (es)
BR (1) BRPI0408556A (es)
CA (1) CA2519125A1 (es)
CL (1) CL2004000573A1 (es)
CO (1) CO5611169A2 (es)
CY (1) CY1105652T1 (es)
DE (1) DE602004002201T2 (es)
DK (1) DK1608407T3 (es)
ES (1) ES2270361T3 (es)
MX (1) MXPA05009978A (es)
NO (1) NO20054260L (es)
PL (1) PL1608407T3 (es)
PT (1) PT1608407E (es)
RU (1) RU2325189C2 (es)
SI (1) SI1608407T1 (es)
TW (1) TWI262084B (es)
UY (1) UY28235A1 (es)
WO (1) WO2004082588A2 (es)
ZA (1) ZA200506920B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
US9943614B2 (en) 2008-06-17 2018-04-17 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
ES2728135T3 (es) 2011-07-20 2019-10-22 Univ Brigham Young Materiales de hidrogel que incorporan un compuesto de elución de ceragenina
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
UA113298C2 (xx) 2011-12-21 2017-01-10 Композиція для догляду за порожниною рота
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
WO2013165574A2 (en) 2012-05-02 2013-11-07 Brigham Young University Ceragenin particulate materials and methods for making same
RU2486905C1 (ru) * 2012-05-28 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Средство для лечения мастита у животных
US9314472B2 (en) 2012-10-17 2016-04-19 Brigham Young University Treatment and prevention of mastitis
WO2014107740A2 (en) 2013-01-07 2014-07-10 Brigham Young University Methods for reducing cellular proliferation and treating certain diseases
CN105492005A (zh) * 2013-02-08 2016-04-13 罗达制药有限公司 治疗包括乳房炎的微生物感染的方法
EP2970280B1 (en) 2013-03-15 2021-07-07 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2014386207B2 (en) 2013-12-20 2019-08-22 President And Fellows Of Harvard College Organomimetic devices and methods of use and manufacturing thereof
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
RU2557691C1 (ru) * 2014-07-25 2015-07-27 Государственное бюджетное учреждение здравоохранения города Москвы "Московский научно-практический Центр оториноларингологии им Л.И. Свержевского" Департамента здравоохранения города Москвы Способ определения длительности лечения активных форм отосклероза
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN104688554A (zh) * 2015-01-30 2015-06-10 柳州两面针股份有限公司 水杨苷在制备口腔护理保健品中的应用
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
WO2016172553A1 (en) 2015-04-22 2016-10-27 Savage Paul B Methods for the synthesis of ceragenins
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
KR101625020B1 (ko) 2016-02-11 2016-06-01 최예도 식기세척기
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
JP6802946B2 (ja) * 2017-09-08 2020-12-23 ドン クック ファーム カンパニー リミテッドＤｏｎｇ Ｋｏｏｋ Ｐｈａｒｍ Ｃｏ．，Ｌｔｄ 難聴の予防または処置のための活性成分としてアボカド油画分を含有する医薬組成物
EP3603645A1 (en) 2018-07-30 2020-02-05 Virbac Novel use of glucocorticoids for the treatment of epithelial microbial infections of a fluid containing organ with a natural exterior orifice in mammals

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636194A (en) * 1969-10-23 1972-01-18 Douglas G Parizeau Composition and method for treating mastitis with therapeutic agents
DE2063896A1 (de) * 1970-12-28 1972-07-20 Dynamit Nobel Ag, 5210 Troisdorf Salbengrundlagen auf der Basis von Triglyceriden gesättigter mittelkettiger Fettsäuren und Verfahren zu deren Herstellung
US4299501A (en) * 1979-08-10 1981-11-10 Ortho Pharmaceutical Corporation Continuous process for the preparation of semisolid dispersions
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1996037476A1 (en) * 1995-05-25 1996-11-28 G.D. Searle & Co. Method of preparing 3-haloalkyl-1h-pyrazoles
MX9701731A (es) * 1995-06-06 1997-10-31 Bayer Ag Composiciones anti-bacterianas oticas, no-irritantes, no-sensibles y no-toxicas para el oido.
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
TR199802049T2 (xx) * 1996-04-12 1999-01-18 G.D.Searle & Co. COX-2 Inhibit�rlerinin �nilac� olarak s�bstit�e edilmi� benzens�lfonamid t�revleri.
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
AR020660A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US7064132B2 (en) * 1999-11-28 2006-06-20 Scientific Development And Research, Inc. Composition and method for treatment of otitis external
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
EP1246621A4 (en) * 1999-12-23 2004-11-24 Nitromed Inc NITROSED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS FOR THEIR USE
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
US6548527B2 (en) * 2000-03-27 2003-04-15 The General Hospital Corporation Treatments for immune-mediated ear disorders
WO2001087328A2 (en) * 2000-05-12 2001-11-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
CA2409123A1 (en) * 2000-06-08 2001-12-13 The University Of Texas System Heterocycle derivatives and methods of use
CA2410632A1 (en) * 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use

Also Published As

Publication number Publication date
RU2005129266A (ru) 2006-03-20
CA2519125A1 (en) 2004-09-30
WO2004082588A3 (en) 2004-12-23
TW200503756A (en) 2005-02-01
PT1608407E (pt) 2006-12-29
CY1105652T1 (el) 2010-12-22
DE602004002201D1 (de) 2006-10-12
WO2004082588A2 (en) 2004-09-30
NO20054260D0 (no) 2005-09-15
JP2006520779A (ja) 2006-09-14
CO5611169A2 (es) 2006-02-28
KR100717433B1 (ko) 2007-05-14
EP1608407A2 (en) 2005-12-28
AU2004222523A1 (en) 2004-09-30
ATE337793T1 (de) 2006-09-15
TWI262084B (en) 2006-09-21
DK1608407T3 (da) 2006-12-04
CN1761487A (zh) 2006-04-19
RU2325189C2 (ru) 2008-05-27
KR20050114249A (ko) 2005-12-05
BRPI0408556A (pt) 2006-03-21
SI1608407T1 (sl) 2006-12-31
ES2270361T3 (es) 2007-04-01
US20040235803A1 (en) 2004-11-25
ZA200506920B (en) 2007-09-26
AR043650A1 (es) 2005-08-03
MXPA05009978A (es) 2005-11-04
PL1608407T3 (pl) 2006-12-29
CL2004000573A1 (es) 2005-01-14
NO20054260L (no) 2005-12-12
DE602004002201T2 (de) 2007-09-20
EP1608407B1 (en) 2006-08-30

Similar Documents

Publication Publication Date Title
UY28235A1 (es) Formulación dispersable de un agente antiinflamatorio
AR043651A1 (es) Composicion farmaceutica dispersable para el tratamiento de mastitis y trastornos oticos
CO5650245A2 (es) Formulaciones dispersable de un agente anti-inflamatorio
AR042537A1 (es) Composiciones farmaceuticas dispersables que contienen antibacterianos para animales productores de leche
AR036266A1 (es) Pelicula para refrescar el aliento
AR036972A1 (es) Tableta bioadhesiva de hidratacion progresiva y liberacion sostenida y su uso en la fabricacion de un agente farmaceutico
BRPI0414320A (pt) composição para tratamento da pele
MY144292A (en) Method of reducing oral tissue inflammation using magnolia extract
WO2007070677A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
US5888523A (en) Topical non-steroidal anti-inflammatory drug composition
CN101889974A (zh) 一种壳聚糖避孕凝胶及其制备方法
CY1108548T1 (el) Βιοπροσκολλητικη γελη βασισμενη σε υδροξυαιθυλοκυτταρινη
AR034517A1 (es) Formulacion farmaceutica
Sachan et al. Effect of Delonix regia (Boj. Ex Hook.) Raf. stem bark extract against experimentally induced ulcers in rats
SV2006001916A (es) Formulaciones farmaceuticas transdermales
PE20070464A1 (es) Forma farmaceutica con liberacion sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph
MD2516B1 (en) Anti-inflammatory, antiseptic and antimycotic medicament in the form of gel
WO2015092719A1 (es) Composiciones acuosas de complejos de cobre, complejos de cobre poliméricos y aloe vera
BRPI0414223A (pt) uso de extratos de gentiana lutea como um agente antimicrobiano
TH10572C3 (th) เจลปิดเนื้อเยื่อในฟัน
CN108432818A (zh) 一种化学合成的农药配方
TH10572A3 (th) เจลปิดเนื้อเยื่อในฟัน
PT1347753E (pt) Composicao topica e metodo para o tratamento da incontinencia urinaria de stress
ES2172818T3 (es) Uso de antagonistas de lh-rh como agente de diagnostico.
AR039314A1 (es) Formulaciones farmaceuticas de liberacion retrasada

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150519